Mike Gorenstein

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) net revenue in 2022 was $91.9 million, a 23% increase compared to $74.4 million in 2021. Q4 2022 Financial Highlights Net revenue of $22.9 million, an 11% decrease compared to $25.8 million in Q4 2021. Gross loss was $234,000, compared to a gross...

After the overwhelming success of last year's Benzinga Cannabis Capital Conference, the team is returning to Florida April 11-12, 2023 with awesome events simultaneously taking place on two stages at Miami Beach's historic Fontainebleau Hotel. To celebrate individuals, entrepreneurs,...

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) launched a CBC-focused product, the Spinach FEELZ THC+CBC Day Trip Mango Lime gummies, utilizing Ginkgo Bioworks’ platform for organism design and development. The Spinach FEELZ Day Trip gummies feature a 3:1 ratio of CBC to THC or 10mg of THC and...

Florida Gets New MMJ Czar Florida Department of Health’s officials recently revealed that Christopher Phillip Kimball agreed to serve as the state’s Office of Medical Marijuana Use, succeeding Chris Ferguson, who served for the past three years. The agency’s spokeswoman Weesam...

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) Q3 2022 net revenue was $20.9 million, a 2.5% increase compared to $20.4 million in Q3 2021. The increase year-over-year was primarily driven by an increase in net revenue in the rest of world segment driven by growth in the Israeli medical market and...

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) released its 2022 second quarter business results, revealing gross profit of $4.1 million in Q2 2022 improved by $19.9 million from Q2 2021. Q2 2022 Financial Highlights Net revenue of $23.1 million in Q2 2022 increased by $7.4 million from Q2 2021. The...

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) launched the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the VESIsorb delivery system. The first VESIsorb formulated product the companies have launched together are the CBD Gel Capsules by Lord...

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) reported Tuesday its 2022 first quarter business results with net revenue growth of 101.61% year-over-year, due to the revenue improvements in the Israeli medical market and the Canadian adult-use market. “I founded Cronos because of the once-...

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) announced that the board of directors has appointed Mike Gorenstein as chairman, president, and CEO, effective March 21, 2022, in connection with Kurt Schmidt's retirement. Gorenstein’s immediate areas of focus include: Delivering margin...

Cronos Group (NASDAQ: CRON) opened Thursday morning at $6.62 a share, but quickly lost ground on the heels of an earnings report showing a second-quarter net loss of $107 million. Cronos also reported a $40-million impairment charge related to a cannabidiol deal with CBD brand Lord...

Cannabis company Cronos Group Inc (NASDAQ: CRON) plans on launching vaping devices in Canada with a focus on safety, quality and proper ingredients, company founder and CEO Mike Gorenstein told CNBC's Jim Cramer. What Happened Cronos opened a cannabinoid device R&D facility in Israel...

Shares of Cronos Group Inc (NASDAQ: CRON) traded higher Thursday morning after the cannabis company reported a four-fold jump in revenue year-over-year in its second quarter results. Cronos said it earned 22 cents per share in the second quarter on revenue of CA$10.237 million. By comparison, the...

Cronos Group Inc (NASDAQ: CRON) announced Friday it reached an agreement to acquire a CBD company with exposure to the United States. What Happened Cronos entered into an agreement to acquire four of Redwood Holding Group's operating subsidiaries, the company said in a press release. Redwood is...

Cronos Group (NASDAQ: CRON) (TSX:CRON) announced Thursday it entered into an agreement to acquire GMP compliant fermentation and manufacturing facility from Apotex Fermentation. The acquisition is expected to be completed during the third quarter, whereas Apotex Fermentation will continue to be in...

Cronos Group (NASDAQ: CRON) on Tuesday announced the appointment of Dr. Todd Abraham as the company's Chief Innovation Officer. Abraham "will be responsible for advancing Cronos Group’s research and development initiatives in cannabinoids with a focus on identifying new disruptive...